Haverford Trust Co Trims Stake in Pfizer Inc. (NYSE:PFE)

Haverford Trust Co lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 26.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 360,380 shares of the biopharmaceutical company's stock after selling 131,837 shares during the quarter. Haverford Trust Co's holdings in Pfizer were worth $9,561,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. PSI Advisors LLC raised its holdings in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after buying an additional 391 shares during the last quarter. D Orazio & Associates Inc. lifted its holdings in shares of Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 391 shares during the period. Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC grew its holdings in Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after acquiring an additional 401 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Bank of America reissued a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Price Performance

PFE stock traded down $0.16 during midday trading on Thursday, reaching $25.05. The stock had a trading volume of 51,260,038 shares, compared to its average volume of 36,817,956. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a market cap of $142.08 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company's fifty day simple moving average is $26.09 and its 200 day simple moving average is $26.97. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.